In pancreatic cancers, TGF-β signaling antagonizes IL1-induced JAK/STAT activation by downregulating IL-1 receptor 1 (IL-1R1) expression and drives the commitment of iCAFs (inflammatory CAFs) to myoCAFs (myofibroblastic CAFs) (107). The gene discussed is TGFB1; the disease is familial pancreatic carcinoma.